The results presented here may help to define a more precise immunological signature of patients affected by CRC, highlighting the role of the tumor microenvironment and extending our knowledge of different immunological signatures involving alterations in complexes driven by CIITA and B2M. The gene discussed is CIITA; the disease is neoplasm.